Summary of adverse events reported in clinical trials with anakinra Download Table From toxicity assessment to adaptive safety care: implementing comprehensive fast track safety evaluation for anticancer drug development ESMO Open Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab Chronic immune related adverse events arising from immune checkpoint inhibitors: an update Journal for ImmunoTherapy of Cancer